Pasithea Therapeutics Corp.(KTTA)

Biotechnology · Miami Beach, FL

$0.45-0.01 (-1.54%)

Delayed quote: Oct 6, 2026, 12:37 PM EDT

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T16:43:17.963Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:43:17.963Z.

Quote observation: 2026-10-06T16:37:08.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 14,966,330
TTM free cash flow · period ending 2026-06-30: -17,781,592

FMP input reference: b407bf9ab9426f7f8731c51b1e955f2cfcbe23f9f3e819a9868889fb687bb4da

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KTTA Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

KTTA Competitors' Price/FCF Ratio

KTTA

Pasithea Therapeutics Corp.

Current

Market Cap

$14.97M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs KTTA

Market Cap

$14.57M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COCP

Cocrystal Pharma, Inc.

vs KTTA

Market Cap

$15.42M

Price/FCF Ratio

N/A

TTM Avg

82.38

3Y Avg

82.38

5Y Avg

82.38

BCDA

BioCardia, Inc.

vs KTTA

Market Cap

$16.04M

Price/FCF Ratio

N/A

TTM Avg

121.92

3Y Avg

75.43

5Y Avg

64.77

ALLR

Allarity Therapeutics, Inc.

vs KTTA

Market Cap

$15.72M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPTI

Karyopharm Therapeutics Inc.

vs KTTA

Market Cap

$15.83M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OBX

Obsidian Therapeutics Inc.

vs KTTA

Market Cap

$14.09M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SINT

Sintx Technologies, Inc.

vs KTTA

Market Cap

$13.83M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs KTTA

Market Cap

$13.78M

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HIND

Vyome Holdings, Inc.

vs KTTA

Market Cap

$13.72M

Price/FCF Ratio

26.16

TTM Avg

28.16

3Y Avg

28.16

5Y Avg

28.16

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Pasithea Therapeutics Corp. (KTTA)	$14.97M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.57M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.42M	N/A	82.38	82.38	82.38
BioCardia, Inc. (BCDA)vs ›	$16.04M	N/A	121.92	75.43	64.77
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.72M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$15.83M	N/A	N/A	N/A	N/A
Obsidian Therapeutics Inc. (OBX)vs ›	$14.09M	N/A	N/A	N/A	N/A
Sintx Technologies, Inc. (SINT)vs ›	$13.83M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.78M	N/A	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$13.72M	26.16	28.16	28.16	28.16

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/FCF Ratio: N/A

KTTA Price/FCF Ratio Metrics

KTTA Competitors' Price/FCF Ratio

Free Cash Flow Valuation

Price/FCF Ratio Formula & Definition

Related Metrics